Journal of cataract and refractive surgery · 2007
Successful treatment of cystoid macular edema with valdecoxib.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Reis Alexander, Birnbaum Florian, Hansen Lutz L, Reinhard Thomas
Аннотация
PURPOSE: To evaluate the safety and efficacy of the COX-2 inhibitor valdecoxib in treating macular edema after cataract surgery.
SETTING: University Eye Clinic, Freiburg, Germany and Reis Medical Institution, Liechtenstein.
METHODS: The COX-2 inhibitor valdecoxib (Bextra) was administered systemically to patients with significant visual loss resulting from macular edema in a prospective clinical trial.
RESULTS: Ten patients were enrolled. Valdecoxib was tolerated well and led to a significant visual improvement within 10 days of therapy in all patients.
CONCLUSION: The fast and persistent control of macular edema with valdecoxib warrants further investigation.
SETTING: University Eye Clinic, Freiburg, Germany and Reis Medical Institution, Liechtenstein.
METHODS: The COX-2 inhibitor valdecoxib (Bextra) was administered systemically to patients with significant visual loss resulting from macular edema in a prospective clinical trial.
RESULTS: Ten patients were enrolled. Valdecoxib was tolerated well and led to a significant visual improvement within 10 days of therapy in all patients.
CONCLUSION: The fast and persistent control of macular edema with valdecoxib warrants further investigation.